Recruiting
Phase 2

Observational Study

Sponsor:

Brigham and Women's Hospital

Code:

NCT06366724

Conditions

ME/CFS

Long COVID

PASC

Eligibility Criteria

Sex: All

Age: 18 - 70

Healthy Volunteers: Not accepted

Interventions

Pyridostigmine

Low-Dose Naltrexone

Placebo

Study Details

Brief summary:

The LIFT will be conducted at Brigham and Women's Hospital (BWH) of Harvard Medical School, focusing on the effect of Pyridostigmine (Mestinon) and Low-Dose Naltrexone (LDN) in subjects aged 18-70 meeting the Canadian consensus criteria (CCC) for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) as well as having specifically Orthostatic Intolerance (OI). Long COVID (LC) subjects will also be included if they meet CCC and have OI.

This double-blind, placebo-controlled study will involve 160 participants randomized into one of four possible groups: Pyridostigmine/LDN (40), Pyridostigmine/Placebo (40), LDN/Placebo (40), Placebo/Placebo (40). The dose of Pyridostigmine will be carefully titrated from 30mg to 60mg three times a day, and the dose of LDN will be titrated from 1.5 mg to 4.5 mg once daily.

The trial includes a scale-back plan, allowing participants to reduce their dosage if they experience intolerance symptoms, with adjustments made during weekly visits. This plan provides a personalized approach to medication tolerance, ensuring participant's safety and comfort throughout the trial.

The time commitment for the participant is approximately three (3) months, and during this time, there will be three (3) in-person visits to BWH and four (4) virtual visits. Study procedures will include two (2) submaximum cardiopulmonary exercise tests, questionnaires (virtually completed), and blood and urine collection. We will be recruiting from the BWH Dyspnea Clinic as well as the Open Medicine Foundation (OMF) StudyME Registry and anticipate the entire trial will take two (2) years to complete.

The LIFT represents a significant endeavor to improve treatment options for ME/CFS patients and contribute to the broader understanding of this debilitating condition.

Conditions

ME/CFS

Long COVID

PASC

Study ID

NCT06366724

Start date

Sep 10, 2024

Status verified date

Oct, 2025

Completion date

Nov, 2026

Anticipated

Primary completion date

Sep, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 70

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. Meet National Academy of Medicine Criteria, Canadian Consensus Criteria (See appendix), and demonstrate orthostatic intolerance for diagnosis of ME/CFS
2. Participant is ≥ 18 and ≤ 70 years of age at screening, inclusive.
3. The onset of symptoms prior to December 2023.
4. Female participant is not pregnant and at least 1 of the following conditions apply:

1. Not a woman of childbearing potential
2. Woman of childbearing potential who agrees to follow the contraceptive guidance. from the time of informed consent.
5. Participant agrees and can adhere to the study requirements for the length of the study.
6. Participant has a body mass index (BMI) range of 17 to 40 kg/m2, inclusive.
7. Participant agrees not to participate in another interventional study while participating in the present study.
8. Participant has a functioning smart phone to download and run the DANA Brain Vital Mobile Application.

Exclusion Criteria:

1. Pregnant, planning to become pregnant, or breastfeeding.
2. Any use of opioid medications within 30 days of screening.
3. Positive urine test for opioids
4. History of alcohol, opioid or other substance misuse
5. Participation in another interventional clinical trial in the last 30 days or planned during the trial period.
6. Allergy to medication components
7. Participant has any condition which, in the investigator's opinion, makes the participant unsuitable for study participation.
8. Participant has diabetes mellitus (type 1 or 2).
9. Participant has undergone an inpatient hospitalization within the 30 days prior to the randomization or has a planned hospitalization or a surgical procedure during the study, which may affect the study assessments, in the opinion of the investigator.
10. Participant has clinically significant respiratory disease (such as chronic obstructive pulmonary disease, cystic fibrosis, severe asthma, lung infections including tuberculosis, sarcoidosis, thoracic endometriosis, pulmonary fibrosis, and lung cancers) and/or cardiac disease (medical history or current clinical findings)
11. Participant has an active malignancy or any other cancer.
12. Participant has initiated an exercise regimen within 4 weeks prior to randomization.

Study Design

Enrollment

160 participants

Anticipated

Allocation

Randomized

Intervention Model

Factorial

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

active comparator: Pyridostigmine/LDN

Pyridostigmine will be taken as liquid suspension three times a day, scaling up from 20mg (1.67mL) to 60mg (5mL) (180mg/day). Low dose naltrexone will be taken as liquid suspension once a day, scaling up from 1.5mL to 4.5mL (4.5mg/day).

active comparator: Pyridostigmine/Placebo

Pyridostigmine will be taken as liquid suspension three times a day, scaling up from 20mg (1.67mL) to 60mg (5mL) (180mg/day). Placebo will be taken as liquid suspension once a day, scaling up from 1.5mL to 4.5mL.

active comparator: Placebo/LDN

Placebo will be taken as liquid suspension three times a day, scaling up from 1.67mL to 5mL. Low dose naltrexone will be taken as liquid suspension once a day, scaling up from 1.5mL to 4.5mL (4.5mg/day).

placebo comparator: Placebo/Placebo

Placebo will be taken as liquid suspension three times a day, scaling up from 1.67mL to 5mL. Placebo will be taken as liquid suspension once a day, scaling up from 1.5mL to 4.5mL .

Interventions

Pyridostigmine

Pyridostigmine timeline:

Weeks 0-2: 20mg TID (1.67 mL TID)

Weeks 2-4: 40mg TID (3.33 mL TID)

Weeks 5-13: 60mg TID (5mL TID)

Low-Dose Naltrexone

LDN timeline:

Weeks 0-2: 1.5mg QD (1.5mL QD)

Weeks 2-4: 3.0mg QD (3.0mL QD)

Weeks 5-13: 4.5mg QD (4.5mL QD)

Placebo

Placebo timeline:

Weeks 0-2: 20mg TID (1.67mL TID)/1.5mg QD (1.5mL QD)

Weeks 2-4: 40mg TID (3.33mL TID)/3.0mg QD (3.0mL QD)

Weeks 5-13: 60mg TID (5mL TID)/4.5mg QD (4.5mL QD)

Primary outcome measure

  • Functional Capacity [ Time Frame: 15 weeks ]
  • Physiologic Response - Oxygen Uptake Efficiency Slope (OUES) [ Time Frame: 13 weeks ]
  • Physiologic Response - Oxygen Utilization (VO2) [ Time Frame: 13 weeks ]
  • Physiologic Response - Heart Rate Recovery (HRR) [ Time Frame: 13 weeks ]

Central Contacts and Locations

Central contacts

Research Coordinator

617-525-6797jsquires1@bwh.harvard.edu

Locations

Brigham and Women's Hospital

Recruiting

Boston, Massachusetts, United States, 02115

Contacts

Clinical Research Coordinator

617-525-6797jsquires1@bwh.harvard.edu

More Information

Sponsor

Brigham and Women's Hospital

Last update posted

Oct 22, 2025

Last verified

Oct, 2025

Keywords

  • Chronic fatigue
  • Mestinon
  • Low Dose Naltrexone
  • Orthostatic Intolerance
  • Post exertional malaise
  • Cognitive Impairment
  • Long COVID

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-24. This information was provided to ClinicalTrials.gov by Brigham and Women's Hospital on 2025-10-22. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.